Pear Bio Revenue and Competitors

London, UK

Location

#9388

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Pear Bio's estimated annual revenue is currently $7.1M per year.(i)
  • Pear Bio's estimated revenue per employee is $155,000

Employee Data

  • Pear Bio has 46 Employees.(i)
  • Pear Bio grew their employee count by 39% last year.

Pear Bio's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Pear Bio?

Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pear Bio News

2022-04-17 - Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...

2022-04-13 - Pear Therapeutics Receives Safer Technologies Program ...

Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain.

2022-03-22 - Pear Therapeutics ripens after SPAC pact, predicts ...

That represented a solid year-over-year drop in Pear's total revenue thanks to ... for example, molecules, biological functions and diseases or phenotypes.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M4615%N/A
#2
$4.5M46-55%$17.8M
#3
$3.8M46-10%N/A
#4
$7.5M4615%N/A
#5
$6.1M4621%N/A